LILLY-B9E-MC-JHQG

Study Sponsor: Lilly

Study Title

Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer

Medicine or Vaccine (generic name)

Gemcitabine

Sponsor Identification Number

B9E-MC-JHQG

Trial Registry Identification Number(#'s)

NCT00006459

Medical Condition

Breast Cancer

Phase

Phase 3

Link to study details on the Lilly Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

Link to study details on EudraCT (if available)

Not available

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

June 2015